 Use of CD81 as a therapeutic target to regulate the intracellular levels of DNTPS (Machine-translati
专利摘要:
The present invention belongs to the field of biomedicine, in particular it addresses the use of agents capable of reducing/inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in the preparation of a medicament for the treatment of diseases in which the volume of dNTPs It is already relevant to screening methods for the identification of said agents. Finally, the present invention provides combination therapies for the treatment of HIV. (Machine-translation by Google Translate, not legally binding) 公开号:ES2688161A2 申请号:ES201700345 申请日:2017-03-30 公开日:2018-10-31 发明作者:María YAÑEZ-MÓ；Henar SUÁREZ MONTERO；Francisco SÁNCHEZ MADRID；Vera ROCHA-PERUGINI 申请人:Universidad Autonoma de Madrid；Fundacion para la Investigacion Biomedica del Hospital Universitario de la Princesa； IPC主号:
专利说明:
USE OF CD81 AS A THERAPEUTIC DIANA TO REGULATE LEVELSDNTPS INTRACELLULARS Technical field The present invention belongs to the field of biomedicine, in particular it is directed to the use of agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in the preparation of a medicament for the treatment of diseases in which the volume of dNTPs It is already relevant to screening methods for the identification of such agents. State of the art SAMHD1 is a ubiquitous expression deoxynucleoside triphosphate phosphohydrolase (dNTPase) that regulates intracellular levels of dNTP (Franzolin et al., 2013, The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells, Proc Natl Acad Sci 110d : 14272-14277). SAMHD1 activity limits, for example, the HIV-1 RT RT in resting monocytes, macrophages, dendritic cells and CD4 T cells (Ballana and Este, 2015, AMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction, Trends Microbiol. 23: 680-692). A high activity of this enzyme (caused, for example, by an increase in its intracellular levels) causes a reduction in the concentration of available dNTPs. In the specific context of HIV infection, an increase in HIV-1 RT and intracellular concentrations of dNTPs was observed in cells from the mouse deficient for SAMHD1 (Behrendt et al., 2013, Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response, Cell Rep. 4: 689-696; Rehwinkel et al., 2013, SAMHD1-dependent retroviral control and escape in mice, Embo J. 32: 2454-2462). Low levels of dNTP prevent double-stranded viral DNA synthesis, blocking subsequent steps in the viral cycle (Baldauf et al., 2012, SAMHD1 restricts HIV-1 infection in resting CD4 (+) T cells, Nat Med. 18: 1682 -1687; Lahouassa et al., 2012, SAMHD1 restricted the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates, Nat Immunol. 13: 223-228). In activated CD4 + T lymphocytes the SAMHD1 expression is reduced (Ruffin et al., 2015, Low SAMHD1 expression following T-cell activation and proliferation renders CD4 + T cells susceptible to HIV-1, Aids, 29: 519-530), and high levels of dNTP allow viral infection (Baldauf et al., 2012; Descours et al., 2012, SAMHD1 restrictedts HIV-1 reverse transcription in quiescent CD4 (+) T-cells, Retrovirology, 9:87). The specific mechanisms for regulating the enzymatic activity of SAMHD1 are yet to be elucidated. In dividing cells that are not restricted to HIV-1 infection, SAMHD1 is phosphorylated in threonine residues 592 (T592) by cyclin-dependent kinases (CDKs) (Cribier et al., 2013, Phosphorylation of SAMHD1 by cyclin A2 / CDK1 regulates its restriction activity towards HIV-1, Cell Rep. 3: 1036-1043; Welbourn et al., 2013, Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1, J Virol. 87: 11516- 11524; White et al., 2013, The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation, Cell Host Microbe, 13: 441-451). This phosphorylation is induced by interleukins 2 (IL-2) and IL-7 in CD4 + T cells (Coiras et al., 2016, IL-7 Induces SAMHD1 Phosphorylation in CD4 + T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle, Cell Rep. 14: 2100-2107). SAMHD1 is also a nucleic acid binding protein and exhibits in vitro exonuclease activity against single stranded DNAs and RNAs (Beloglazova et al., 2013, Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction, J Biol Chem. 288: 8101-8110; Ryoo et al., 2016, The ribonuclease activity of SAMHD1 is required for HIV-1 restriction, Nat Med. 20: 936-941). This RNase activity, which also plays a role in restricting HIV-1 infection (Choi et al., 2015, SAMHD1 specifically restricts retroviruses through its RNase activity, Retrovirology, 12:46; Ryoo et al., 2014, The ribonuclease activity of SAMHD1 is required for HIV-1 restriction, Nat Med. 20: 936-941), would have DNA-RNA duplex specificity like those that occur during HIV-1 RT. However, recent studies cast doubt on the requirement of phosphorylation in T592 for the control of nuclease and phosphohydrolase activities (Antonucci et al., 2016, SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity, Nature medicine, 22: 1072-1074; Bhattacharya et al., 2016, Effects of T592 phosphomimetic mutations on tetramer stability and dNTPase activity of SAMHD1 cannot explain the retroviral restriction defect, Scientific reports, 6: 31353; Ruiz et al., 2015, Cyclin D3- dependent control of the dNTP pool and HIV-1 replication in human macrophages, Cell Cycle, 14: 1657-1665; Tang et al., 2015, Impaired dNTPase activity of SAMHD1 by phosphomimetic mutation of Thr-592, J Biol Chem. 290: 26352-26359), suggesting additional regulatory mechanisms. The human immunodeficiency virus (HIV) primarily infects CD4 T lymphocytes, monocytes and dendritic cells. After binding to the CD4 receptor, the viral envelope glycoproteins interact with a corrective protein, the CXCR4 or CCR5 chemokine receptors, which induce conformational changes that allow fusion between viral and cellular membranes (Blumenthal et al., 2012, HIV entry and envelope glycoprotein-mediated fusion, J Biol Chem. 287: 40841-40849). Replication of HIV-1 requires a reverse transcription (RT) step and the insertion of viral DNA into the host genome. However, the temporal sequencing of these events is not yet fully defined. Disassembly of the viral particle can occur in the plasma membrane, just after fusion, inducing RT, subsequently being the pre-integration complex (PIC) actively transported to the nucleus (Ambrose, Z., and C. Aiken, 2014 , HIV-1 uncoating: connection to nuclear entry and regulation by host proteins, Virology, 454-455: 371-379 .; Arhel, N. 2010, Revisiting HIV-1 uncoating, Retrovirology, 7:96 .; Warrilow et al., 2009, Maturation of the HIV reverse transcription complex: putting the jigsaw together, Rev Med Virol. 19: 324-337). Alternatively, the viral capsid could be transported to the perinuclear region, disassembly and RT occurring gradually (Ambrose and Aiken, 2014; Arhel, 2010; Hu, WS, and SH Hughes, 2012, HIV-1 reverse transcription, Cold Spring Harb Perspect Med. 2; Warrilow et al., 2009). A third model proposes that, after fusion, the viral capsid would remain intact and RT would occur during transport, being completed in the nuclear pore, just before the PIC was transferred to the nucleus (Ambrose and Aiken, 2014; Arhel, 2010 ; Hu and Hughes, 2012). Numerous cell molecules, including tetraspanins, regulate HIV-1 infection (Rocha-Perugini et al., 2014, PIP: choreographer of actin-adapter proteins in the HIV-1 dance, Trends Microbiol. 22: 379-388 ; Thali, M. 2009, The roles of tetraspanins in HIV-1 replication, Curr Top Microbiol Immunol. 339: 85-102). Tetraspanins establish homotypic interactions with other tetraspanins, as well as with transmembrane receptors, lipids and intracellular proteins, organizing multimolecular membrane complexes called Tetraspanin-enriched microdomains (TEMs) (Charrin et al., 2014, Tetraspanins at a glance, J Cell Sci 127: 3641-3648; Yanez-Mo et al., 2009, Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes, Trends in cell biology, 19: 434-446). Through TEMs, tetraspanins modulate the function of their associated molecules, playing an important role in a wide variety of physiological and pathological processes, including immunity and viral infections (Levy and Shoham, 2005, The tetraspanin web modulates immunesignalling complexes, Nat Rev Immunol. 5: 136-148; Rocha-Perugini et al., 2015 , Function and Dynamics of Tetraspanins during Antigen Recognition and Immunological Synapse Formation, Front Immunol. 6: 653; van Spriel and Figdor, 2010, The role of tetraspanins in the pathogenesis of infectious diseases, Microbes Infect. 12: 106-112). Tetraspanins CD9 and CD81 negatively regulate membrane fusion induced by HIV-1 (Gordon-Alonso et al., 2006, Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion, J Immunol. 177: 51295137), and a mutant Deletion of the N-terminal domain of tetraspanin CD63 blocks the entry of HIV by preventing expression on the cell surface of CXCR4 (Yoshida et al., 2008, A CD63 mutant inhibits T-cell tropic human immunodeficiency virus type 1 entry by disrupting CXCR4 trafficking to the plasma membrane, Traffic, 9: 540-558). CD63 is also important for viral RT (Fu et al., 2015, Tetraspanin CD63 is a regulator of HIV-1 replication, Int J Clin Exp Pathol. 8: 1184-1198; Li et al., 2011, A post-entry role for CD63 in early HIV-1 replication, Virology, 412: 315-324). The assembly of HIV-1 virus preferably occurs in TEMs (Ono, 2010, Relationships between plasma membrane microdomains and HIV-1 assembly, Biol Cell. 102: 335-350), although the role of tetraspanins as co-release factors It has not yet been well established (Thali, 2011, Tetraspanin functions during HIV-1 and influenza virus replication, Biochem Soc Trans. 39: 529-531). The use of HIV medications for the treatment of HIV infection is known as antiretroviral therapy (ART). HIV medications are grouped into six classes, depending on how they fight the infection. The six classes are: • Non-nucleoside reverse transcriptase inhibitors (ITINN) • Nucleoside analogue reverse transcriptase inhibitors (ITIN) • Protease Inhibitor (IP) • Fusion inhibitors • CCR5 receptor antagonists (also known as entry inhibitors) • Integrase chain transfer inhibitor (INSTI) In general, a first HIV infection treatment regimen for an adult or adolescent includes two ITINs along with an INSTI, an ITINN or an IP administered with a cobicistat or ritonavir booster. Both cobicistat and ritonavir increase (reinforce) the efficacy of IP. However, as HIV reproduces, it can suffer mutations and become resistant to HIV medications. Drug resistance can cause HIV treatment to fail (information obtained from https://infosida.nih.gov). Therefore, new methods are necessary both for the treatment / prevention of HIV infection and for the treatment and / or prevention of diseases in which the volume of dNTPs is relevant, as well as screening methods for the identification of agents (compounds) useful in said methods of treatment and / or prevention. Brief Description of the Invention In a first aspect, the present invention provides the use of agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in the preparation of a medicament for the treatment and / or prevention of diseases in which the volume of dNTPs It is relevant. In a second aspect, the present invention provides screening methods to identify agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 comprising the steps of: a) Select candidate agents, preferably from a library of compounds; b) Determine if any of these agents is capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in cells expressing both proteins; c) Select those agents that promote the reduction / inhibition described in step b); Y, d) Optionally, produce those agents selected in step c). In a third aspect, the present invention provides a combination of medications or combination therapy for the treatment of HIV comprising at least three medications selected from at least two different classes of medications for treating HIV, characterized in that the combination comprises at least a medicine belonging to the class of analogue reverse transcriptase inhibitor drugs of nucleosides, wherein said medicament is an agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1. Brief description of the figures Figure 1. The C-terminal domain of CD81 mediates its association with SAMHD1. A) Western HDL of SAMHD1 of human primary T lymphocyte lysates precipitated with biotinylated peptides formed by the C-terminal sequence of the tetraspanins CD81, CD9 and CD151. The results for the negative control of naked sepharose and the total lysate are shown. B) Lysates of human primary T lymphocytes were immunoprecipitated with antibodies against SAMHD1 and CD81. The membranes were analyzed for SAMHD1 and CD81. The results of the control microspheres incubated with the cell lysate and the entire cell lysate are shown. C) Hela / R5 cells (upper panels) or T lymphoblasts (lower images) were seeded on PLL coated coverslips, fixed, permeabilized and immunostained for CD81 and SAMHD1 and analyzed by confocal microscopy. A single confocal plane is shown. Bar = 10µm D) Hela / R5 cells transfected with control siRNA (siControl) or CD81 siRNA (siCD81) were seeded for 2h on coverslips covered with PLL (10µg / ml), or monoclonal antibodies anti-CD9 (VJ1 / 20, 10µg / ml), anti-CD4 (HP2 / 6, 10µg / ml) or antiCD81 (5A6, 10µg / ml), fixed, permeabilized and immunostained for SAMHD1 (polyclonal antibody) and analyzed by confocal microscopy. The images show a single confocal plane in ventral position, bar = 10 µm. The graphs show the quantifications of the number of observed aggregates (aggregates / cell) data are the mean ± SEM of 50 cells from 3 independent experiments analyzed by Tukey post-test ANOVA. E) Primary T lymphoblasts seeded on coverslips covered with PLL were labeled with antibodies to SAMHD1 and CD81 following the instructions of the Duo / link kit manufacturer. The contribution with SAMHD1 and CD147 was used as a negative control, and that of CD81 / ERM as a positive control, bar = 10µm. The graphs show the number of positive points per cell; Each point on the graph represents an individual cell, the bar represents the mean of the scatter plot, the values obtained were analyzed by ANOVA and Dunns post-test. Figure 2. The expression of CD81 regulates the reverse transcription of the HIV-1 X5-tropic virus A) Temporal evolution of the HIV-1 RT measured by quantitative PCR of the products early (graphs on the left for each type of virus) or late (graphs on the right for each type of virus) at 24 or 48 hours post-infection. Hela / R5 cells expressing GFP (black), CD81GFP (dotted line) or CD81ɅcytGFP (gray) were infected with the R5-tropic virus HIV-1 BaL or with VSV-G-HIV. The values indicate the mean induction ± SEM calculated from 4 independent experiments performed in triplicate. B) Hela / R5 cells transfected with control siRNA (upper graphics, black) siRNA CD81 (upper panels, gray) or with CRISPR / Cas9-CD81 (lower panels, gray) or untransfected cells (lower panels, black) were infected and analyzed as in a. The values indicate the average induction calculated from 2 independent experiments performed in triplicate. In each case the first graph on the left corresponds to the early products and the one on the right to the late ones. C) Hela / R5 cells pretreated for 5 days with cytopermeable peptides consisting of the sequence of the C-terminal region of CD81 (CD81pept, gray) or a disordered version (scramble, black) at a concentration of 2 µM were infected and analyzed as in a. The a-c values were analyzed by ANOVA and Bonferroni post-test. Figure 3. CD81 regulates the reverse transcription of the HIV-1 X4-tropic virus in human primary T lymphoblasts. A) Primary T lymphoblasts were previously treated with the control peptide (scramble, black) or CD81pept (gray) at a concentration of 2 µM for 5 days, and subsequently infected with the strain of HIV-1 X4-tropic NL4-3 ( upper graphs) or VSV-G-HIV (lower graphs). Early (left) and late (right) products from the HIV-1 virus RT were analyzed by quantitative PCR at 24 and 48 hours post-infection. The values indicate the mean induction ± SEM of two independent experiments performed in triplicate, analyzed by ANOVA and Bonferroni post-test. B) Primary T lymphoblasts transfected with control siRNA (black) or CD81 siRNA (gray) were infected with the HIV-1 strain X4-tropic NL4-3 and the viral RT was measured as in A. The data comes from a representative experiment of two. The box shows the Western blot obtained from the total lysates of the T lymphoblasts used in this experiment. ERM was used as load control. Figure 4. CD81 negatively regulates the dNTPase activity of SAMHD1. A) Jurkat J77 T cells transfected with control siRNA (black) or against CD81 (gray) were infected with the HIV-1 NL4-3 viral strain, and early RT products were measured by qPCR at the indicated times. The values represent the mean induction ± SEM of two experiments independent performed in triplicate. B) Jurkat J77 T cells pretreated with a 2 µM concentration of control peptide (black) or CD81pept (gray) for 5 days were infected with the HIV-1 NL4-3 viral strain, and the virus RT was analyzed in the same way what in A. C) The content of dNTP was measured by an assay based on HIV RT in Hela / R5 cells, Hela / R5 CRISPR / Cas9-CD81 (left graph), and human primary T lymphoblasts transfected with control siRNA or against CD81 (right graph). Values represent the mean induction ± SEM of 4 (Hela / R5) or 2 (T lymphoblasts) independent experiments analyzed by paired Student t. D) Content of dNTP in Hela / R5 cells that overexpress GFP, CD81GFP or CD81ɅcytGFP. The values represent the mean induction ± SEM of 3 independent experiments analyzed by ANOVA with Tukey post-test. Figure 5. CD81 regulates the expression of SAMHD1. A) Human primary T lymphoblasts were transfected with control siRNA or against CD81, and Hela / R5 cells were transfected or not with CRISPR / Cas9-CD81. The cells were lysed and analyzed for CD81, SAMHD1 and the phosphorylated form of SAMHD1 by Western-blot. Tubulin and cofilin were used as load controls. The membranes come from a representative experiment of two (Blastos, left) and three (Hela / R5, right); The numbers below each membrane indicate the signal ratio between CD81, SAMHD1 and the phosphorylated form of SAMHD1 with respect to its load control. B) Hela / R5 cells transfected with CRISPR / Cas9-CD81 (gray line) or untreated (black line) were fixed, permeabilized, immunostained for SAMHD1 and CD81, and analyzed by flow cytometry. Histograms show a representative experiment of 3. The negative control corresponds to cells labeled only with the secondary antibody. C-D) cells in which CD81 (CRISPR / Cas9-CD81) or Hela / R5 control was removed were treated with the vehicle (control) or with the indicated concentrations of C) MG132 or D) NH4Cl for 6 hours. The cells were lysed and analyzed by Western-blot for SAMHD1 and ERM as load control. The graphs show the relationship between the signal of SAMHD1 and ERM as mean induction ± SEM of c) 3 or d) 2 independent experiments analyzed by ANOVA with Bonferroni post-test. Figure 6. SAMHD1 is partially enriched in early endosomes. A) Hela / R5 cells were transfected with control siRNA or against CD81, and allowed to adhere to fibronectin coated coverslips (FN) for 4 hours, fixed, permeabilized, fixed. immunolabelled for SAMHD1 and analyzed by confocal microscopy. The images show a single confocal plane, the arrows show the accumulation of SAMHD1 in intracellular structures with circular morphology, bars = 10µm. The graphs show the quantification of the number (structures / cell, upper graphs) and the area (µm2 / cell, lower graphs) of the cytoplasmic structures observed. The data represent the mean ± SEM of 230 cells (n = 4 independent experiments) analyzed by t-Student. B) Hela / R5 cells were treated with a 2µM concentration of control peptide or CD81pept and analyzed in the same manner as in A (n = 400 cells of 4 independent experiments), t-Student. C) Hela / R5 cells were transfected with GFP, CD81GFP or CD81ɅcytGFP, and analyzed as in A. Data represent the mean ± SEM of 20 cells (n = 2 independent experiments) analyzed by ANOVA with Tukey post-test D) Se allowed the adhesion of Hela / R5 cells transfected with control siRNA or against CD81 for 4h to coverslips covered with fibronectin. The samples were fixed, permeabilized, immunolabelled and analyzed by confocal microscopy. The images show SAMHD1, EEA1, LAMP1, and the co-location of SAMHD1 / EEA1. A single confocal plane is shown, bars = 10µm. The graphs represent the co-location between SAMHD1-EEA1 quantified in groups of 3D images of confocal microscopy. In the upper graph, the Pearson coefficient; in the lower graph% of the signal of SAMHD1 that colocalizes with EEA1 with respect to the signal of SAMHD1 in the whole cell. Data represent the mean ± SEM of 3 independent experiments (n = 200 cells) analyzed by t-Student. Figure 7. A) Jurkat J77 T cells were fixed, permeabilized, immunostained for SAMHD1 and analyzed by flow cytometry. For the negative control they were labeled only with secondary antibody. B) Hela / R5 cells were transfected with siRNA against CD81 (siCD81) or control (siControl) (left panel); or with CRISPR / Cas9-CD81 or without transfecting (central panel). Cells were lysed and analyzed for CD81, and for tubulin or p150glued as loading controls. The images show the representative membranes. The values under western blots represent the value of the ratio between the CD81 / tubulin signal obtained in the experiments with siRNA. Jurkat J77 T cells were transfected with siRNA against CD81 (siCD81) or control siRNA (siControl), and analyzed as Hela (right panel). C) Hela / R5 cells treated with the control (black) or CD81 (white) siRNA were immunolabelled for CD4, CCR5 and various tetraspanins and analyzed by flow cytometry. The graphs represent indicate the mean induction ± SEM of 4 experiments independent. The differences are not significant. D) Hela / R5 cells treated or not treated with CRISPR / Cas9-CD81, were analyzed as described in C). Figure 8. A) Hela / R5 cells were transfected with control siRNA or against CD81, or treated with a 2 µM concentration of scramble or CD81 peptide, and seeded on coverslips treated with fibronectin for 2h. After this they were fixed, permeabilized, immunostained for SAMHD1 and analyzed by confocal microscopy. The graphs show the quantification of the number (counts / cell, upper graphs) and the area (µm2 / cell, lower graphs) of the circular-shaped structures observed in the cytoplasm. The values represent the mean ± SEM of 2 independent experiments (n = 60 cells in the siRNA experiments, and n = 100 in the peptide treatment experiments). Data were analyzed using t-Student, * p <0.05, ** p <0.01. B) Hela / R5 cells treated with siRNA or with the peptides were seeded for 18 hours on coverslips treated with fibronectin, and analyzed as was done in A. Values represent the mean ± SEM of 2 independent experiments (n = 90 cells in the siRNA experiments, and n = 20 cells in the experiments with the peptides). Data were analyzed using the t-Student test * p <0.05, ** p <0.01. C) Hela / R5 cells were transfected with GFP, CD81GFP or CD81ɅcytGFP, adhered for 2 h in crystals covered with fibronectin and analyzed as in a (beads / cell, left graph) and area (µm2 / cell, graph right). The data are the mean ± SEM of two independent experiments (n = 40 cells) analyzed by one-way ANOVA and Tukey’s test. Figure 9. A-B) Hela / R5 cells transfected with siRNA were adhered for 4 h on coverslips covered with fibronectin, fixed, permeabilized, immunolabelled and analyzed by confocal microscopy. The images show SAMHD1 and (A) HGS / HRS or (B) CD63. A single confocal plane is shown, bars = 10µm. Detailed description of the invention Other features and advantages of the invention will be apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, although indicating specific embodiments of the invention, are only provided by way of illustration, given that various changes and modifications within the spirit and scope of the invention will be apparent to those skilled in the art from the present detailed description. Unless defined otherwise, all the technical and scientific terms used herein have the same meaning as normally understood by a person skilled in the art to which the present invention belongs. As used herein, the terms "express", "expressing" and "expression" refer to allowing or making information in a gene or DNA sequence manifest itself, for example by producing a protein by activation of cellular functions involved in the transcription and translation of a corresponding gene or DNA sequence. A DNA sequence is expressed in or by a host cell to form an "expression product" such as a protein. It can also be said that the expression product itself, for example, the resulting protein, is "expressed" or "produced" by the host cell. The term "gene expression" refers to the process by which the nucleic acids of a gene are used to direct transcription resulting in protein synthesis. The gene expression process comprises 2 main steps: 1) Transcription: the production of messenger RNA (mRNA) by an RNA polymerase using the DNA sequence as a template. This stage continues with the processing or maturation of the resulting mRNA molecule. 2) Translation: the use of mRNA to direct protein synthesis. After this Second stage post-translational modifications of the protein may occur. In the context of the present invention, "RNA interference (RNAi)" is understood as an RNA molecule that suppresses the expression of specific genes by mechanisms known globally as ribointerference or RNA interference. The interfering RNAs are small molecules (from 20 to 25 nucleotides) that are generated by fragmentation of longer precursors. RNAi comprise the following groups of molecules: - Small interference RNA (or small interfering RNA siRNA) are perfectly complementary double stranded RNA molecules of approximately 20 or 21 nucleotides (nt) with 2 nucleotides unpaired at each 3 'end. Each strand of RNA has a 5 'phosphate group and a 3' hydroxyl (-OH) group. This structure comes from the processing carried out by Dicer, an enzyme that cuts long double stranded RNA molecules (dsRNA, double stranded RNA) into several siRNAs. One of the strands of the siRNA (the 'antisense' strand) is assembled into a protein complex called RISC (RNA-induced silencing complex), which uses the siRNA strand as a guide to identify the complementary messenger RNA. The RISC complex catalyzes the cutting of the complementary mRNA into two halves, which are degraded by the cellular machinery, thus blocking the expression of the gene. The siRNAs can also be introduced exogenously into the cells using transfection methods based on the complementary sequence of a particular gene, in order to significantly reduce their expression. - miRNA (or miRNA in English "micro-RNA") are small interfering RNAs that are generated from specific precursors encoded in the genome, which when transcribed fold into intramolecular hairpins that contain imperfect complementarity segments. Precursor processing generally occurs in two stages, catalyzed by two enzymes, Drosha in the nucleus and Dicer in the cytoplasm. One of the strands of the miRNA (the 'antisense' strand), as with siRNAs, is incorporated into a complex similar to the RISC (from the “RNAinduced silencing complex”). Depending on the degree of complementarity of the miRNA with the mRNA, the miRNAs can either inhibit the translation of the mRNA or induce its degradation. However, unlike the siRNA pathway, miRNA-mediated mRNA degradation begins with the enzymatic removal of the poly (A) tail of the mRNA. In the context of the present invention, the term "RNA antisense oligonucleotide" refers to a single strand of RNA that is complementary to a specific sequence. This sequence of antisense RNA hybridizes with a particular mRNA thus inhibiting its translation, since translation of the mRNA requires a simple strand of RNA. Thus, the antisense RNA oligonucleotide inhibits the synthesis of a given protein. On the other hand, RNase H degrades RNA-DNA complexes, so that hybridization of antisense RNA oligonucleotide to a specific DNA sequence will also cause degradation of said DNA sequence. In the context of the present invention, the term "vector" refers to a small DNA fragment, obtained from a virus, a plasmid, or a cell of a higher organism into which heterologous genetic fragments can be inserted and which They are commonly used to artificially transport this heterologous genetic material to another cell, where it can be replicated, expressed and / or inserted into the genome of the host cell. In general, the vector itself is a DNA sequence that consists of a transgene and a longer sequence that serves as a "skeleton" of the vector. It can be single or double chain. Optionally, it may be formed, or comprise, modified nucleic acids, such as, for example, methyl phosphate or main phosphorothioate chains. As used herein, the term "approximately" means the indicated value ± 1% of its value, or the term "approximately" means the indicated value ± 2% of its value, or the term "approximately" means the indicated value ± 5% of its value, the term "approximately" means the indicated value ± 10% of its value, or the term "approximately" means the indicated value ± 20% of its value, or the term "approximately" means the indicated value ± 30% of its value; preferably the term "approximately" means exactly the indicated value (± 0%). The terms "treatment" or "therapy" encompass both prophylactic and curative methods of a disease or condition, since both are aimed at maintaining or restoring health. Regardless of the origin of pain, discomfort or disability, its improvement, through the administration of an appropriate agent, should be interpreted as therapy or therapeutic use in the context of the present application. The term "reduction" or "reduce" or "inhibit" or "inhibition" refers to reductions below the baseline level. For example, basal levels are normal at in vivo levels before, or in the absence of, an agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1. "Optional" or "optionally" means that the event or circumstance described below may or may not occur, and that the description includes cases in which said event or circumstance occurs and cases in which it does not. The term "combination therapy" or "combination of medications" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present description. Such administration encompasses the co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple separate capsules for each active ingredient. In addition, such administration also encompasses the use of each type of therapeutic agent in a sequential manner. In any case, the treatment regimen will provide beneficial effects of the combination of compounds in the treatment of the conditions or disorders described in the present description. The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will be necessary to achieve the objective of reducing or eliminating said disease or disorder. As used herein, the terms "prevent", "preventing" and "prevention" refer to methods to prevent or prevent the development of a disease or disorder or delay the recurrence or occurrence of one or more symptoms of a disorder in a subject resulting from the administration of a prophylactic agent. Tetraspanin CD81 (in humans, Gene ID: 975, updated on 5-Feb-2017; UniProtKB - P60033) regulates the availability of dNTPs (deoxyribonucleotide triphosphate) through its direct association with the cellular enzyme SAMHD1 and the regulation of its expression , and therefore its dNTPase activity. A reduction / inhibition of the interaction between tetraspanin CD81 and the cellular enzyme SAMHD1 (in humans, Gene ID: 25939, updated on 5-Feb-2017; UniProtKB - Q9Y3Z3) reduces the availability of dNTPs, since this reduction / inhibition of the interaction between CD81 and SAMHD1 causes an increase in the intracellular levels of SAMHD1, and therefore an increase in the levels of dNTPase activity, which leads to a reduction in the levels of available dNTPs. The reduction / inhibition of the interaction between CD81 and SAMHD1 increases the basal levels of the enzyme SAMHD1; In absence of interaction with CD81, SAMHD1 is retained in the early endosomes, so its degradation by proteasome is prevented. The reduction / inhibition of the interaction between tetraspanin CD81 and the cellular enzyme SAMHD1 can be achieved by direct means, that is, a physical disruption of this interaction (e.g., by peptides, small molecules or antibodies that specifically block the interaction between CD81 and SAMHD1) or by indirect means, that is, a reduction in CD81 expression levels (e.g., by small interference RNAs (siRNA), micro RNAs (miRNA), shRNAs, vectors for gene therapy, such as vectors for gene therapy comprising the CRISP / Cas9 system). This reduction / inhibition of the interaction between tetraspanin CD81 and the cellular enzyme SAMHD1, either directly or indirectly, is relevant in the treatment of diseases in which the volume of dNTPs is relevant, such as infections caused by retroviruses, infections caused by DNA viruses and DNA viruses that have retrotranscription steps in their viral cycle, and Aicardi-Goutières syndrome. In particular, the reduction / inhibition of the interaction between tetraspanin CD81 and the cellular enzyme SAMHD1 is relevant in the early replication of the human immunodeficiency virus-1 (HIV-1 or, for its acronym in English, HIV-1), since the dNTPase activity of the enzyme SAMHD1 reduces the amount of dNTPs available for the synthesis of cDNA of HIV viral reverse transcriptase, thus preventing virus replication. Therefore, in a first aspect, the present invention provides the use of agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in the preparation of a medicament for the treatment and / or prevention of diseases in which The volume of dNTPs is relevant. Therefore, the present invention provides agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 for use in medicine, in particular in methods of treatment and / or prevention of diseases in which the volume of dNTPs is relevant. As indicated above, the reduction / inhibition of the interaction between CD81 tetraspanin and the SAMHD1 cellular enzyme can be achieved by direct means, that is, a physical disruption of this interaction (e.g., by peptides, small molecules or antibodies that specifically block the interaction between CD81 and SAMHD1) or by indirect means, that is, a reduction in CD81 expression levels (eg, by small interfering RNAs (siRNA), micro RNAs (miRNA), shRNAs, vectors for gene therapy, such as vectors for gene therapy comprising the CRISP / Cas9 system. Preferably, the diseases in which the volume of dNTPs is relevant are selected from the group consisting of infections caused by retroviruses, infections caused by DNA viruses and by DNA viruses that have in their viral cycle retrotranscription steps, and Aicardi syndrome - Goutières. The person skilled in the art knows the infections caused by retroviruses. Retroviruses are viruses with single-stranded RNA genome of positive polarity that replicate through an intermediate form of double-stranded DNA. This process is carried out by an enzyme, retrotranscriptase or reverse transcriptase (RT), which directs the synthesis of DNA through RNA. Once it has been passed from single stranded RNA to DNA, this DNA is inserted into the DNA of the infected cell where it behaves like one more gene. There are 4 human retroviruses identified: human immunodeficiency virus type 1 (HIV-1), type 2 (HIV-2) and human T-cell lymphotropic viruses type I and II (HTLV-I and HTLV- II). All are housed in T lymphocytes. Human immunodeficiency viruses induce an immune response that causes lysis of infected cells causing severe immunosuppression. HTLVI / II viruses cause the immortalization of infected lymphocytes, generating an uncontrolled replication of them, and therefore lymphoproliferation. Reverse transcriptase, reverse transcriptase or retrotranscriptase (RT) is a DNA polymerase-like enzyme, whose function is to synthesize double stranded DNA using single stranded RNA template, that is, catalyze reverse transcription or reverse transcription. In a preferred embodiment, infections caused by retroviruses are caused by one or more viruses that are selected from the group consisting of HIV and HTLV, preferably are selected from the group consisting of HIV-1, HIV-2, HTLV-I and HTLV-II. In a preferred embodiment, infections caused by DNA viruses are caused by herpes viruses, preferably selected from the group consisting of herpes simplex virus type I (HSV). 1), herpes simplex virus type II (HSV-2), varicella-zoster virus or human herpes virus 3, Epstein-Barr virus or human herpes virus 4, cytomegalovirus or herpes human virus 5, human herpes virus 6, herpes human virus 7 and Kaposi's Sarcoma virus or herpes human virus 8. In a preferred embodiment, infections caused by DNA viruses that have in their viral cycle retrotranscription steps are caused by a virus that is selected from the group consisting of infections caused by hepatitis B virus. In an even more preferred embodiment, the disease in which the volume of dNTPs is relevant is the infection caused by HIV. Preferably, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of small interfering RNA (siRNA), micro RNA (miRNA), shRNA, peptides, small molecules, antibodies and vectors for gene therapy, preferably vectors for gene therapy comprising the CRISP / Cas9 system. Even more preferable, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of siRNA, peptides, antibodies and vectors for gene therapy comprising the CRISP / Cas9 system. The agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 (active ingredient) can be administered in vivo in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, that is, the material can be administered to a subject without causing any undesirable biological effect or interacting in a harmful manner with any of the other components of the composition pharmaceutical in which it is contained. The vehicle, of course, is selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as is well known to one skilled in the art. The effective dosages and administration schedules of the compositions comprising the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 described herein can be determined empirically, and making such determinations is within the experience in the technique. The dosage ranges for administration of the compositions are those large enough to produce the desired reduction / inhibition effect of the association of tetraspanin CD81 with the enzyme SAMHD1. The dosage should not be so large as to cause adverse side effects, such as unwanted cross reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient, the route of administration, or if other drugs are included in the regimen, and can be determined by one skilled in the art. The dosage can be adjusted by the individual doctor in case of any contraindication. The dose may vary, and may be administered in one or more daily dose administrations, for one or several days. Guidance can be found in the literature for appropriate dosages for the given classes of pharmaceutical products. Small interfering RNA (siRNA) (siRNA, small interfering RNA) or silencing RNA is a class of double stranded RNA, which generally has a length of approximately 20 to 25 nucleotides and is highly specific for the nucleotide sequence of its target messenger RNA, thereby interfering with the expression of the respective gene. It intervenes in the mechanism called RNA interference (RNA interference, RNAi), whereby the siRNA interferes with the expression of a specific gene, reducing it, as described above. In the context of the present invention, if the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is an siRNA, said reduction / inhibition is performed indirectly; siRNA interferes with the expression of the gene encoding the CD81 protein, so that the expression of this gene is reduced / inhibited (and, as a consequence, CD81 protein levels are also reduced / inhibited). Since CD81 protein levels are reduced / inhibited, the association of CD81 tetraspanin with the enzyme SAMHD1 is also reduced / inhibited, and intracellular levels of SAMHD1 increase, thereby increasing its dNTPase activity, reducing the amount of available dNTPs. Preferably, the small interfering RNA is selected from the group consisting of sequences that comprise or, alternatively, consist of CAATTTGTGTCCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9). A micro RNA (miRNA or miRNA) is a single-stranded RNA, generally between 21 and 25 nucleotides in length that has the ability to regulate the expression of other genes. MiRNAs are RNA molecules transcribed from DNA genes, but they are not translated into proteins. Generally, a miRNA is complementary to a part of one or more messenger RNA (mRNA), and thus regulates gene expression, as described above. For example, in the context of the present invention, if the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is a miRNA, it may be complementary to a part of the mRNA of the CD81 protein, reducing / inhibiting the translation of this mRNA to the CD81 protein. The levels of CD81 protein will therefore be reduced, thus reducing / inhibiting the association of CD81 tetraspanin with the enzyme SAMHD1. A shRNA ("short hairpin RNA" or "small hairpin RNA") is an artificial RNA molecule that can be used to silence the expression of a target gene by interfering RNA. The expression of shRNA in cells is generally achieved by transport in plasmids or viral or bacterial vectors. A peptide is a molecule composed of the union of several amino acids by peptide bonds. In the context of the present invention, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 may be a peptide that binds either CD81 or SAMHD1 and interferes with the association of both molecules, reducing it or inhibiting it. In a preferred embodiment, the agent capable of reducing / inhibiting the association of CD81 with SAMHD1 is a peptide, preferably a peptide comprising the sequence CCGIRNSSVY (SEQ ID NO .: 10) or a sequence that can compete with SEQ ID NO .: 10. The agent capable of reducing / inhibiting the association of CD81 with SAMHD1, in the case that it is a peptide, may also comprise any sequence that allows the peptide to penetrate a cell membrane such as, for example, a sequence of seven RRRRRRRCCGIRNSSVY arginines ( SEQ ID NO .: 1), or the peptide can be encapsulated in a liposome or nanocapsule that allows the peptide to pass through a cell membrane. In addition, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 may be an antibody that interferes with the association of CD81 with SAMHD1, reducing or inhibiting it. Preferably, the antibody is an antibody that recognizes specifically the C-terminal domain of the CD81 protein, where the C-terminal domain of the CD81 protein is the CCGIRNSSVY sequence (SEQ ID NO .: 10). Preferably, the antibody is a monoclonal antibody that specifically recognizes and binds to the C-terminal domain of the CD81 protein, thereby preventing (reducing / inhibiting) the association between CD81 and SAMHD1. In a preferred embodiment, the C-terminal domain of the CD81 protein is SEQ ID NO .: 10. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, that is, molecules that contain an antigen binding site that specifically binds (immunoreacts) with, for example, the C-terminal domain of the CD81 protein. Examples of immunologically active fragments include F (ab) and F (ab ’) 2 fragments that can be generated by treating the antibody with an enzyme such as pepsin. The antibodies can be polyclonal (typically include different antibodies directed against different determinants or epitopes) or monoclonal (directed against a single determinant in the antigen). In a preferred embodiment, the C-terminal domain of the CD81 protein is SEQ ID NO .: 10. The antibody can also be recombinant, chimeric, human or humanized, synthetic or a combination of any of the foregoing. A "recombinant antibody or polypeptide" (rAC) is an antibody that has been produced in a host cell that has been transformed or transfected with the nucleic acid encoding the polypeptide or antigen, or produces the polypeptide or antigen as a result of recombination. homologous In another embodiment of this first aspect of the present invention, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is a vector for gene therapy, also called a gene vector. A gene vector is an agent that transfers genetic information to an organism. For example, the gene vector may be a plasmid comprising a gene of interest or a sequence of interest. Preferably, the gene therapy vector or gene vector comprises the CRISPR / Cas9 system. By administering the Cas9 protein and appropriate guide RNAs to a cell, the genome of this cell can be cut at the desired sites, the sequences of which will be complementary to those of the guide RNAs used. This allows the functional elimination of genes. The CRISPR / Cas9 system can be used for gene editing; in the context of the present invention, the system CRISPR / Cas9 is used for the functional elimination of the gene encoding the CD81 protein, thereby inhibiting the expression of CD81 in the target cell and thereby reducing / inhibiting the association of the CD81 tetraspanin with the enzyme SAMHD1. Preferably, the gene therapy vector or gene vector comprising the CRISPR / Cas9 system comprises as a target sequence a sequence comprising or, alternatively, consisting of CACCGGCTGGCTGGAGGCGTGATCCGT (SEQ ID NO .: 11) or CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: ). In an even more preferred embodiment, the disease in which the volume of dNTPs is relevant is the infection caused by HIV and the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of Small interference RNA selected from the group consisting of sequences that comprise or, alternatively, consist of CAATTTGTGT CCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9), a peptide comprising the sequence CCGIRNSSVY (SEQ ID NO .: 10), a sequence that can compete with SEQ ID NO .: 10 and / or a sequence that can also comprise any sequence that allows the peptide to penetrate a cell membrane such as, for example, a sequence of seven arginines (SEQ ID NO .: 1) and a vector for gene therapy comprising the CRISP / Cas9 system comprises as a target sequence a sequence that comprises or, alternatively consists of, CACCGGCTGGCTGG AGGCGTGATCCGT (SEQ ID NO .: 11) or CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: 12). In a second aspect, the present invention provides screening methods to identify agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1. The screening methods according to the present invention comprise or, alternatively, consist of the steps of: a) Select candidate agents, preferably from a library of compounds; b) Determine if any of these agents is capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in cells expressing both proteins; c) Select those agents that promote the reduction / inhibition described in step b); Y, d) Optionally, produce those agents selected in step c). In the context of the present invention, the term "screening method" is understood as a method that allows to select compounds (agents) capable of promoting a certain change measurable by in vitro methods known in the art, in a biological sample or in a non-human model animal to which said compound (agent) has been administered, as compared to a similar and comparable non-human biological sample or animal sample, to which the compound (agent) has not been administered. Said screening method may also include an additional phase of isolation of the selected compound or of the selected compounds. The candidate agents according to step a) are preferably selected from the group consisting of small interfering RNA (siRNA), micro RNA (miRNA), shRNA, peptides, small molecules, antibodies and vectors for gene therapy, preferably therapy vectors genetics comprising the CRISP / Cas9 system, as defined in the context of the first aspect of the present invention. The person skilled in the art is aware of available methods to determine if any of said agents is capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in cells expressing both proteins (step b) of the screening method of the present invention. ). For example, precipitation experiments using lysates of primary T lymphoblasts and biotinylated peptides with the C-terminal sequence of different tetraspanins coupled to sepharose spheres with streptavidin are described in section 2 of the examples herein for the purpose of studying whether SAMHD1 specifically binds to CD81 C-terminal peptides In this same section, the association between endogenous SAMHD1 and CD81 molecules was confirmed in co-immunoprecipitation assays using lysates of primary T lymphoblasts. Other methods that can be used to study the association of CD81 and SAMHD1 proteins are in situ proximity ligation assays such as Duolink®, cross-linking assays and using purified fusion proteins on chromatography columns. by affinity In addition, as detailed above, a reduction in the expression levels of the CD81 protein produces, at least indirectly, a reduction / inhibition of the association of the CD81 tetraspanin with the enzyme SAMHD1. Therefore, if any of said agents of step a) of the screening method of the present invention is capable of reducing the expression of CD81, this agent is also capable of reducing / inhibiting the association of CD81 tetraspanin with the enzyme SAMHD1. For example, RT-PCR (polymerase chain reaction-reverse transcription) can be used to quantify CD81 mRNA levels and immunoblot (Western blot) or flow cytometry can be used to quantify levels of protein In a third aspect, the present invention provides a combination of medications or combination therapy for the treatment of HIV. The combination of medicaments according to the third aspect of the present invention comprises at least three medications selected from at least two different classes of medicaments for treating HIV, and comprises at least one medicament belonging to the class of transcriptase inhibitor medicaments. reverse nucleoside analogue, in which said medicament is an agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1. In general, the initial treatment regimen for HIV includes three or more HIV medications from at least two different classes of HIV medications. HIV medications are grouped into six classes of medications depending on how they fight HIV infection. These six classes of medications include nucleoside analogue reverse transcriptase inhibitors (ITIN), non-nucleoside reverse transcriptase inhibitors (ITINN), protease inhibitors (IP), fusion inhibitors, entry inhibitors (also called CCR5 receptor antagonists) and integrase chain transfer inhibitors (INSTI). There are also the so-called pharmacokinetic enhancers. Preferably, the combination of medicaments according to the present invention comprises two nucleoside analogue reverse transcriptase inhibitors (ITIN), together with an integrase chain transfer inhibitor (INSTI). At least one of the ITINs is an agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 as described in the present description. Optionally, the combination of medicaments according to the present invention further comprises a non-nucleoside reverse transcriptase inhibitor (ITINN) and / or a protease inhibitor (IP), optionally administered with a cobicistat or ritonavir booster . The following table shows the HIV medications authorized by the Food and Drug Administration (FDA, “Https://infosida.nih.gov/education-materials/fact-sheets/21/58/medicamentos-contra-el-vihautorizados-por-la-fda”) of the United States for the treatment of such infection in the country. HIV medications appear according to the class of medication and are identified by their generic name. HIV medications authorized by the FDA Medication class Generic name (Other names and acronyms) Nucleoside analogue reverse transcriptase inhibitors (ITIN) This class of medications blocks reverse transcriptase, an enzyme that HIV needs to replicate. abacavir (abacavir sulfate, ABC) didanosine (slow-release didanosine, dideoxinosine, enteric coated didanosine, ddI, ddI EC) Emtricitabine (FTC) lamivudine (3TC) stavudine (d4T) tenofovir disoproxil fumarate (tenofovir DF, TDF) zidovudine (azidothymidine, AZT, ZDV) Non-nucleoside reverse transcriptase inhibitors (ITINN) This class of medications binds and then alters reverse transcriptase, an enzyme that HIV efavirenz (EFV) etravirine You need to replicate. (ETR) nevirapine (slow-release nevirapine, NVP) rilpivirine (rilpivirine hydrochloride, RPV) Protease Inhibitor (IP) This class of medications blocks the HIV protease, an enzyme that HIV needs to replicate. atazanavir (atazanavir sulfate, ATV) darunavir (darunavir ethanolate, DRV) fosamprenavir (calcium fosamprenavir, FOS-APV, FPV) indinavir (indinavir sulfate, IDV) nelfinavir (nelfinavir mesylate, NFV) ritonavir (RTV) * Although ritonavir is a protease inhibitor, it is usually used as a pharmacokinetic enhancer as recommended in the Clinical Guidelines for the use of antiretroviral agents in adults and adolescents with HIV-1 infection (Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents) and in the Clinical Guidelines for the use of antiretroviral agents in pediatric patients with HIV infection (Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection). saquinavir (saquinavir mesylate, SQV) tipranavir (TPV) Fusion inhibitors This class of medications prevents HIV from penetrating the CD4 lymphocytes of the immune system. enfuvirtide (T-20) Entry inhibitors This class of medications blocks the proteins in the CD4 lymphocytes that HIV needs to penetrate them. Maraviroc (MVC) Integrase Inhibitors This class of medications blocks HIV integrase, an enzyme that HIV needs to replicate. dolutegravir (DTG) elvitegravir (EVG) raltegravir (raltegravir potassium, RAL) Preferably, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of small interfering RNA (siRNA), micro RNA (miRNA), shRNA, peptides, small molecules, antibodies and vectors for gene therapy, preferably vectors for gene therapy comprising the system CRISPR / Cas9, as defined in the context of the first aspect of the present invention. Even more preferable, the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of siRNA, peptides, antibodies and vectors for gene therapy comprising the CRISP / Cas9 system, as it is have defined in the context of the first aspect of the present invention. In a preferred embodiment, the small interfering RNA is selected from the group consisting of sequences that comprise or, alternatively, consist of CAATTTGTGT CCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9). In a preferred embodiment, the peptide comprises the sequence CCGIRNSSVY (SEQ ID NO .: 10), a sequence that can compete with SEQ ID NO .: 10 and / or a sequence that can also comprise any sequence that allows the peptide to penetrate a cell membrane, such as a sequence of seven arginines (SEQ ID NO .: 1). In another preferred embodiment, the antibody is an antibody that specifically recognizes the C-terminal domain of the CD81 protein. In a preferred embodiment, the C-terminal domain of the CD81 protein is SEQ ID NO .: 10. In another preferred embodiment, the gene therapy vector comprising the CRISPR / Cas9 system comprises as a target sequence a sequence that comprises or, alternatively, consists of, CACCGGCTGGCTGGAGGCGTGATCCGT (SEQ ID NO .: 11) or CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: 12) . The following examples merely serve to illustrate the present invention. Examples Tetraspanins modulate different stages in the cycle of infection of the human immunodeficiency virus (HIV-1). Tetraspanin CD81 regulates the entry of the virus and its exit; however, it is unknown if CD81 controls other phases of the viral cycle. The inventors of the present invention have identified SAMHD1 as a molecule associated with CD81 in T lymphocytes. SAMHD1 is a deoxynucleoside triphosphate phosphohydrolase (dNTPase) that acts as a cellular inhibitor of HIV-1 virus reverse transcription (RT). The results shown here indicate that CD81 is directly associated with SAMHD1 through its C-terminal domain. Overexpression of CD81 greatly increases viral retrotranscription, while depletion of CD81 inhibits the early stages of virus replication. The C-terminal region of CD81 is crucial for its ability to regulate the activity of SAMHD1, regulating in this way the concentration and intracellular availability of deoxynucleoside triphosphate (dNTP) and consequently the retrotranscription of HIV-1. In the absence of tetraspanin, SAMHD1 accumulates in early endosomal compartments and its degradation via proteasome is blocked. Together, these results indicate that strategies that inhibit CD81 function inhibit HIV retrotranscription by controlling intracellular levels of dNTPs through SAMHD1. 1. Materials and Methods Cells The Hela P4.R5 MAGI cell line (HELA / R5) was obtained from the NIH AIDS Reagent Program (reference number 3580) AIDS division, NIAID, NIH: P4R5 MAGI, from Dr. Nathaniel Landau (Charneau et al., 1994, HIV-1 reverse transcription: A termination step at the center of the genome, Journal of molecular biology, 241: 651-662) and were cultured in DMEM (Sigma) supplemented with 10% FCS and 1µg / ml puromycin (Sigma ). On the other hand, peripheral blood lymphocytes from healthy patients were isolated and cultured following the previously described guidelines (Rocha-Perugini et al., 2013, CD81 controls sustained T cell activation signaling and define the maturation stages of cognate immunological synapses, Molecular and cellular biology, 33: 3644-3658). Hela / R5 cells (8x106), human T lymphoblasts (2x107), or Jurkat J77 cells (2x107) were washed twice with HBSS (Hank's Balanced Salt Solution, Lonza) and transiently transfected by electroporation with siRNA (1µM) or plasmid DNA (20 µg) in OPTIMEM medium (Gibco, Invitrogen) at 240 V and 34ms (Gene Pulser II, Bio-Rad). This transfection was performed in duplicate with a difference of 48 hours between both pulses, and the experiments were carried out 48 hours after the last one. Overexpression, silencing or gene deletion were confirmed by cytometry or western blotting. Reagents and constructions Peptides with the sequences RRRRRRRCCGIRNSSVY (CD81pept, SEQ ID NO .: 1) or RRRRRRRYSVNICRGCSS (Scrambled, SEQ ID NO .: 2), labeled at the N-terminal end with tetramethylrodamine (TAMRA) were obtained from LifeTein. Biotinylated peptides in their N-terminal end and carriers of an SGSG sequence connected to the C-terminal domain of the proteins of interest, were obtained from Ray Biotech (described previously (Perez-Hernandez et al., 2013, The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries towards exosomes, The Journal of biological chemistry, 288: 11649-11661; Tejera et al., 2013, CD81 regulates cell migration through its association with Rac GTPase, Molecular biology of the cell, 24: 261-273) Both the AAUUCUCCCGAACGUGUCACGU siRNA control (siControl, SEQ ID NO .: 13) and the CD81 CAATTTGTGTCCCTCGGGC siRNA (siCD81, SEQ ID NO .: 3) were purchased in Eurogentec. Three different sequences to silence CD81 have been previously validated, achieving phenotypes similar in other systems (Rocha-Perugini et al., 2013, CD81 controls sustained T cell activation signaling and define the maturation stages of cognate immunological synapses, Molecular and cellular biology, 33: 3644-3658; Tejera et al., 2013, CD81 regulates cell migration through its association with Rac GTPase, Molecular biology of the cell, 24: 261-273). Pull-down, immunoprecipitation and immunoblot assays The biotinylated peptides at the N-terminal end (30nmol) were conjugated to 40 µl streptavidin-sepharose (GE Healthcare). Pull-down assays were performed as previously described (Tejera et al., 2013, CD81 regulates cell migration through its association with Rac GTPase, Molecular biology of the cell, 24: 261-273) using extracts obtained from T lymphoblasts and These were analyzed by Western blotting. Briefly, the cells were washed with cold saline phosphate buffer (PBS) and subsequently lysed using 1% NP-40 in PBS in the presence of protease and phosphatase inhibitors (Complete, PhosSTOP; Roche). The lysates were washed for two hours at 4 ° C with streptavidin sepharose (GE Healthcare), after which they were incubated for 2 h at 4 ° C with biotinylated peptides immobilized in streptavidin sepharose spheres. For immunoprecipitation assays, human primary T lymphoblasts (2x107) were lysed using 0.5% NP-40 in PBS with protease and phosphatase inhibitors. The lysates were pre-cleared for 2 h at 4 ° C with G-Sepharose protein (Amersham Biosciences) and subsequently incubated 2 h at 4 ° C in the presence of anti-CD81 5A6 mAb (produced in the laboratory of Dr. S. Levy, Standford, USA (Takahashi et al., 1990, TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen, J Immunol 145: 2207-2213) and sold by Santa Cruz Biotechnology with the reference number: sc-23962) or anti-SAMHD1 Ab (Sigma) immobilized on sepharose G protein microspheres. After washing with lysis buffer, the complexes were eluted with Laemmli buffer and analyzed by PAGE-SDS. For the immuno-blot, both untreated cells and cells grown for 6 h at 37 ° C in the presence of different concentrations of ammonium chloride (NH4Cl, Sigma) or MG132 (Sigma) were lysed with 1% Triton X-100 in PBS in presence of protease and phosphatase inhibitors. All membranes were revealed using FUJIFILM LAS-4000 after being first incubated with specific antibodies and then with secondary antibodies coupled to peroxidase (Pierce). Primary antibodies were used against: SAMHD1 (polyclonal; Sigma), CD81 (5A6 mAb), α-tubulin (Sigma), p150glued (BD Biosciences), cofilin (Abcam), and ERM (90.3; generously provided by Dr. H Furthmayr, Standford, USA). The intensity of each of the bands was quantified using ImageGauge (FUJIFILM) and the results were normalized with respect to the intensity of the signal from the load controls. Flow cytometry and fluorescence confocal microscopy For flow cytometry the cells were fixed in 2% paraformaldehyde (PFA; Electron Microscopy Sciences), for the analysis of intracellular proteins they were permeabilized in 0.5% Triton X-100 and stained with the appropriate primary antibodies, followed by antibody labeling secondary (Invitrogen). The primary antibodies used were: anti-CCR5 (Santa Cruz), anti-SAMHD1 (Sigma), anti-CD82 (TS82b, generously supplied by Dr. E. Rubinstein, Villejuif, France), and antibodies produced in our laboratory (anti-CD9 (VJ1 / 20), anti-CD151 (LIA1 / 1), anti-CD63 (Tea3 / 18), and anti-CD4 (HP2 / 6)) (Barreiro et al., 2005, Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation, Blood, 105: 2852-2861; Valenzuela-Fernandez et al., 2005, Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection, Molecular biology of the cell, 16: 5445-5454; Yanez-Mo et al., 1998, Regulation of endothelial cell motility by complexes of tetraspan molecules CD81 / TAPA-1 and CD151 / PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions , The Journal of cell biology, 141: 791-804). The analysis of the samples was performed using a FACSCantoII (BD) flow cytometer, and the results were processed using BD FACSDIVA (BD) or FlowJo (Inc) software. For immunomarkers, the cells were adhered on poly-L-lysine (PLL; Sigma) matrices, or on monoclonal antibodies anti-CD4, -CD81 or -CD9 (10 µg / ml) for 2 h; or in fibronectin coated coverslips (20 µg / ml, Sigma) for 2, 4 or 18 h at 37 ° C, fixed with 4% PFA, and permeabilized with 0.5% Triton X-100 PBS for 5 min. Samples were stained with specific primary antibodies, followed by incubation with secondary antibodies coupled to Alexa-Fluor fluorochromes (Invitrogen), and mounted using the ProLong medium (Invitrogen). The primary antibodies used were: anti-CD81 (5A6 mAb), antiSAMHD1 (mAb and polyclonal; Sigma), anti-EEA1 and -CD63 (Santa Cruz), anti-HGS / HRS (Abcam), and labeled anti-LAMP-1 with Alexa-647 (BioLegend). For the in situ Duolink ligation assay, the cells were fixed, blocked and labeled with the antibody against SAMHD1, CD81 (5A6 mAb), ERM (90.3) or CD147 (VJ1 / 9 mAb (Gutierrez-Lopez et al. , 2011, The sheddase activity of ADAM17 / TACE is regulated by the tetraspanin CD9, Cellular and molecular life sciences: CMLS, 68: 3275-3292); produced in our laboratory) for 1 h at 37 ° C. The secondary antibodies included in the Duolink (Sigma) proximity ligation kit were added to visualize the proximity of both molecules in the membrane. The images were obtained by means of a Leica TCS-SP5 confocal microscope coupled to an inverted DMI6000B epifluorescence microscope with an oil immersion HCX PL APO lambda blue 63X / 1.4 lens, and Las-AF (Leica Microsystems) acquisition software, or alternatively by means of a ZEISS LSM700 confocal coupled to an inverted epifluorescence microscope (Observer.Z1) with a Pan APO Chromat 63X / 1.4 oil immersion lens, and the ZEN 2009 acquisition software (Carl Zeiss Microscopy GmbH). The images were analyzed with the ImageJ (NIH) program. Pearson’s coefficient values and% colocalization between SAMHD1 and EEA1 were calculated from three-dimensional sections with Imaris (Bitplane). The SAMHD1 signal from the nucleus was excluded from the analysis. Preparation and infection of HIV-1 virus The preparation of the wild form of HIV-1 NL4-3 (X4-tropic) or BaL (R5-tropic), and the recombinant virus VSV-G-pseudotyped was performed as described previously (Gordon-Alonso et al., 2013 , Actin-binding protein drebrin regulates HIV-1-triggered actin polymerization and viral infection, The Journal of biological chemistry, 288: 28382-28397). For the analysis of the HIV-1 RT, Hela / R5 cells were infected with 100ng of HIV-BaL per well of p24 or with 50 ng per well of p24 of the VSV-G-HIV virus, while the primary T lymphocytes or Jurkat J77 cells were infected with 100ng of HIV-1 NL4-3 virus by 106 cells or 200 ng by 106 cells in the case of VSV-G-HIV. After 2h of infection, the cells were washed and incubated at 37 ° C for 24 and 48 hours, lysed in 0.2% NP-40, and the total genomic DNA was extracted using the QiAmp DNA miniKit (Qiagen). Reverse transcription analysis of HIV-1 was performed by amplification of genomic DNA by quantitative PCR using SYBR Green PCR master mixture (Applied Biosystem): oligo 5´CAGGATTCTTGCCTGGAGCTG-3´ (SEQ ID NO .: 4) and reverse oligo 5 'GGAGCAGCAGGAAGCACTATG-3' (SEQ ID NO .: 5) for early reverse transcription products and oligo 5´-TGTGTGCCCGTCTGTTGTGT-3´ (SEQ ID NO .: 6) and reverse oligo 5´-CGAGTCCTGCGTCGAGAGAT-3´ (SEQ ID NO .: 7) for late transcription products. The β-actin gene was amplified to measure DNA concentration and for normalization of results. Each measurement was made in triplicate. Intracellular dNTP measurement For the analysis and quantification of dNTP, the cells were collected, lysed in 65% cold methanol, and vortexed for 2 min. The extracts were incubated at 95 ° C for 3 min, and the supernatant was collected and evaporated in a speed-vacuum. Samples were processed for single nucleotide incorporation assays as described in (Diamond et al., 2004, Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase, The Journal of biological chemistry, 279: 51545- 51553). Each dNTP (dATP, dCTP, dGTP and dTTP) was detected separately, and for the analysis of the levels contained in cells that overexpress or lack CD81 the levels were normalized against the levels measured in the control cells. Statistic analysis All statistical analyzes were performed with GraphPad Prism (GraphPad Software Inc.). The p-value was calculated using the two-tailed t-Student test, ANOVA the Bonferroni, Tukey or Dunn post-test as appropriate for each data set. The level of statistical significance was defined as * p <0.05, ** p <0.01, and *** p <0.001. 2. Results CD81 is associated with SAMHD1 In this example, the possible association between CD81 and SAMHD1 has been investigated. To test the interaction between CD81 and SAMHD1, we conducted precipitation experiments using lysates of primary T lymphoblasts and biotinylated peptides with the C-terminal sequence of different tetraspanins coupled to sepharose spheres with streptavidin. These experiments revealed that SAMHD1 specifically bound the C-terminal peptides of CD81, while no interaction was observed with those of other tetraspanins (CD9 and CD151) (Figure 1A). The association between endogenous SAMHD1 and CD81 molecules was confirmed in co-immunoprecipitation assays using lysates of primary T lymphoblasts. SAMHD1 was detected in the immunoprecipitates of CD81 and vice versa (Figure 1B). These results indicate that SAMHD1 and CD81 are directly associated through the C-terminal domain of CD81. SAMHD1 is not expressed in immortalized lines of T lymphocytes, such as Jurkat J77 or CEM (Figure 7A). However, enzyme expression was detected both in the cytoplasm and in the nucleus of primary T lymphocytes and Hela cells (Figure 1C). Although CD81 and SAMHD1 co-immunoprecipitan (Figure 1B), a clear co-localization of both molecules was not observed by double staining in resting cells (Figure 1C), suggesting a transient interaction. Therefore, the location of SAMHD1 was studied after cross-linking of tetraspanin. For this, Hela / R5 cells, which stably express CD4 and CCR5, were seeded for 2 hours on coverslips coated with specific antibodies against the CD81 or CD9 tetraspanins, or against the HIV-1 receptor, the CD4 molecule, which also is associated with tetraspanin CD81 (Levy and Shoham, 2005, The tetraspanin web modulates immune-signalling complexes, Nat Rev Immunol. 5: 136-148), or on poly-L-lysine (PLL) as a control. Cells seeded on PLL or anti-CD9 antibodies showed weak staining SAMHD1 in the ventral zone of the cytoplasm in optical sections acquired by confocal microscopy (Figure 1D), in accordance with the absence of association between SAMHD1 and the peptides of the C-terminal region of CD9 in precipitation tests. Hela / R5 seeded on anti-CD81 or anti-CD4 antibodies showed clear accumulations of SAMHD1 in patches in the ventral zone of the cell (Figure 1D). Interestingly, the grouping of SAMHD1 observed after cross-linking of both membrane proteins was canceled in cells in which the expression of CD81 was reduced by transfection of siRNA (siCD81) (Figure 1D), suggesting that the cross-linking of both CD81 and CD4 can induce the accumulation of SAMHD1 in the plasma membrane in a CD81 dependent manner. In addition, in situ ligation assays by proximity revealed protein-protein interactions in a significant number of non-stimulated primary human T lymphoblasts (Figure 1E). These experiments included the co-staining of SAMHD1 / CD147 as a negative control, as long as CD147 is a membrane receptor with an expression even greater than that of CD81. As a positive control we use the CD81 / ERM pair, whose interaction has been described occurs in the U lypoblast of T lymphoblasts (Yanez-Mo et al., 2009, Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes, Trends in cell biology , 19: 434-446), corroborating that the proximity ligation signal could be obtained in cotintions between a membrane receptor and intracellular connector. CD81 positively regulates the reverse transcription of HIV-1 Since SAMHD1 modulates HIV infectivity through the regulation of the RT step, the following that was addressed in this example was the possible role of CD81 as a modulator of said viral cycle step. Hela / R5 cells were transiently transfected with GFP, GFPCD81 (CD81GFP) or a CD81 mutant lacking the C-terminal cytosolic region (CD81cytGFP) (Tejera et al., 2013, CD81 regulates cell migration through its association with Rac GTPase, Molecular biology of the cell, 24: 261-273). The cells thus transfected were infected with wild-type R5-tropic HIV-1 virus (BaL strain), which recognizes CCR5 as a co-receptor. Early and late products of viral RT were measured by quantitative PCR at both 24 and 48h post-infection. The expression of CD81GFP in Hela / R5 cells increased the HIV-1 RT compared to the controls of cells transfected with GFP (Figure 2A, left panels). This increase was dependent on the C-terminal domain of CD81, since the levels of viral RT products were similar in Hela / R5 cells expressing the CD81cytGFP mutant and control cells expressing GFP (Figure 2A, left). To exclude the possibility that the effects observed by the expression of CD81GFP were due to effects on virus entry (Gordon-Alonso et al., 2006, Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion, J Immunol. 177 : 5129-5137), the same type of assays were performed using a recombinant virus with the VSV envelope (VSV-G-HIV). The pseudovirus VSV-G-HIV enters the cell by binding the glycoprotein G of the VSV to the plasma membrane allowing the analysis of the HIV-1 RT independently of its entry. In this model, Hela / R5 cells expressing CD81GFP again showed a large increase in RT, while cells expressing the CD81cytGFP mutant showed similar levels to control cells transfected with GFP (Figure 2A, panels in the right). These results indicate that overexpression of CD81 specifically increases HIV-1 RT through intracellular connections mediated by the C-terminal domain, and independently of its effects on virus entry. In contrast, reduction of CD81 by siRNA (Figure 7B, upper panel), or complete deletion by CRISPR / Cas9 technology (CRISPR / Cas9-CD81; Figure 7B, lower panel) in Hela / R5 cells reduced RT of HIV-1 for both the wild virus of the BaL strain and for VSV-G-HIV (Figure 2B). Depletion of CD81 in Hela / R5 cells with siRNA or CRISPR / Cas9 did not affect the expression levels of CD4, CCR5 or CD82, CD9, CD151 or CD63 tetraspanins (Figure 7D-E). To corroborate the involvement of the C-terminal domain of CD81 in the regulation of HIV-1 RT, Hela / R5 cells were treated with fluorescent cytopermeable peptides corresponding to said C-terminal sequence (CD81pept) or a disordered version as a control (scramble) ). This CD81 peptide functionally remedies the effects of CD81 silencing in different models (Tejera et al., 2013, CD81 regulates cell migration through its association with Rac GTPase, Molecular biology of the cell, 24: 261-273). Hela / R5 cells pre-treated with the cytopermeable peptides were infected with wild virus (BaL strain) or VSV-G-HIV, and RT was analyzed. Pre-treatment of Hela / R5 with CD81pept specifically decreases HIV-1 RT compared to scramble controls (Figure 2C), suggesting that CD81 positively modulates HIV-1 RT through molecular interactions that take place through of your C-terminal domain. In a more physiological model, we investigated whether CD81 modulates the HIV-1 RT in primary cells, using a strain of HIV-1 X4-tropic that uses CXCR4 as a co-receptor. T lymphoblasts were pre-treated with scramble or CD81pept peptides, and infected with wild X4-tropic viruses (strain NL4-3) or VSV-G-HIV. Treatment with the C-terminal CD81 blocking peptides clearly prevented HIV-1 RT when the early and late products of said RT were analyzed by quantitative PCR (Figure 3A). A decrease in HIV-1 RT could also be observed by RNA interference silencing (Figure 3B). Together, our results suggest that CD81 positively regulates the HIV-1 RT in both R5-like and X4-tropic strains. CD81 regulates the dNTPase activity of SAMHD1 To determine whether the function of CD81 in HIV-1 RT depended on the regulation of SAMHD1 activity, we analyzed the effects of CD81 silencing on T cells of the Jurkat J77 line, which do not express SAMHD1 (Figure 7A). In these cells, silencing of CD81 (Figure 7C) or treatment with the C-terminal CD81 peptides did not affect the levels of HIV-1 RT products compared to control cells (Figure 4A-B), indicating that CD81 does not affect the RT of HIV-1 RT in the absence of SAMHD1. SAMHD1 dNTPase activity was directly analyzed by quantifying the intracellular content of dNTPs in cell lysates after overexpression or depletion of CD81. In parallel to the effects observed in viral RT, the set of dNTP was significantly reduced in depleted cells for CD81 compared to controls, both in Hela / R5 CRISPR / Cas9-CD81 and primary T lymphoblasts transfected with CD81 siRNA (Figure 4C). Similar results were obtained when Hela / R5 cells or human primary T lymphoblasts were treated with the CD81 C-terminal peptides (CD81pept) compared to control cells treated with the scrambled peptide. In contrast, overexpression of CD81GFP in Hela / R5 cells increased dNTP levels, while those levels were not affected by the overexpression of CD81cytGFP that was similar to that of GFP control cells (Figure 4D). These results suggest that CD81 regulates the dNTPase activity of SAMHD1. CD81 regulates the degradation of SAMHD1 by the proteasome and its subcellular location Next, we investigate the mechanism by which CD81 would regulate the activity of SAMHD1. Interestingly, the depletion of CD81 increased the expression of SAMHD1, detected by immunoblot of total cell lysates or by flow cytometry, both in primary T lymphoblasts silenced for CD81 (Figure 5A), and in Hela / R5 cells lacking expression of CD81 after transfection with CRISPR / Cas9 (Figure 5A-B). However, no differences were observed in the amount of phosphorylated SAMHD1 in T592 (Figure 5A). To study whether the increase in SAMHD1 expression was related to an altered degradation of the protein, we treated cells with MG132 inhibitors, which prevents degradation by the proteasome, or with ammonium chloride (NH4Cl), which blocks acidification of lysosomes. . SAMHD1 expression was twice as high in control Hela / R5 cells after treatment with MG132 (Figure 5C), while it was only slightly affected by increasing concentrations of NH4Cl (Figure 5D), indicating that proteasome degradation is the main route to SAMHD1 replacement. In CRISPR / Cas9-CD81 cells, baseline expression of SAMHD1 was increased, but the subsequent increase after treatment with MG132 was completely abolished (Figure 5C), suggesting that CD81 is important for the degradation of SAMHD1 by the proteasome. The treatment of Hela / R5 CRISPR / Cas9-CD81 cells with NH4Cl was still able to slightly increase the expression of SAMHD1, suggesting that the lysosomal degradation pathway was not affected, in any case slightly favored after proteasome blockage due to the absence of CD81 (Figure 5D). Since the deletion of CD81 increases the expression levels of SAMHD1 protecting the enzyme from degradation by the proteasome (Figure 5); and that the cross-linking of CD81 induces the accumulation of SAMHD1 in the plasma membrane (Figure 1D), it was decided to study whether the deletion or blockage of CD81 could affect the subcellular location of SAMHD1. Hela / R5 cells transfected with CD81 siRNA or control, were seeded on fibronectin for different times, fixed, permeabilized and stained for SAMHD1. In the absence of CD81, SAMHD1 accumulated in circular cytoplasmic structures. These structures were only observed in a few control cells, and their size was smaller than in silenced cells for CD81 (Figure 6A and Figure 8A-B). Similar results were obtained when Hela / R5 cells were treated with the C-terminal CD81 peptides (Figure 6B and Figure 8A-B). Accordingly, the presence of enriched cytoplasmic circular structures in SAMHD1 it was reduced in cells overexpressing CD81GFP while no differences were observed between Hela / R5 cells expressing CD81cytGFP or GFP (Figure 6C and Figure 8C). To characterize these intracellular structures, the CD81 siRNA or control transfected Hela / R5 cells were co-stained with antibodies against SAMHD1 and markers of different intracellular compartments, and analyzed by confocal microscopy. No co-location was observed between SAMHD1 and late endosome markers (HGS / HRS), multivesicular bodies (CD63) or lysosomes (LAMP-1) (Figure 6D and Figure 9). Interestingly, intracellular structures that accumulated SAMHD1 partially colocalized with EEA1, a marker of early endosomes. SAMHD1 / EEA1 colocalization was increased in silenced cells for CD81 compared to Hela / R5 control, as quantified by Pearson's coefficient and the frequency of SAMHD1 colocation with EEA1 compared to the total SAMHD1 signal (Figure 6D). Together these results show that the deletion of CD81 regulates the expression of SAMHD1 protecting the enzyme from proteasome degradation by subcellular compartmentalization in early endosomes. 3. Discussion It has been shown that CD81 tetraspanin regulates the HIV-1 RT through its molecular association with SAMHD1 that controls its expression and subcellular localization. Solid evidence of the association of CD81 with SAMHD1 in primary human T lymphoblasts is shown by: i) precipitation with synthetic peptides containing the C-terminal domain sequence of CD81 but not that of other tetraspanins (CD9 and CD151), thus confirming the binding specificity of SAMHD1 to CD81; ii) coinmunoprecipitation of the endogenous CD81 and SAMHD1 molecules in both directions (immunoprecipitating CD81 and revealing for SAMHD1 and vice versa) using lysis conditions with detergents (0.5% NP-40) that break the TEMs, preventing indirect connections; Y iii) by in situ ligation tests by proximity. This last test does not demonstrate a direct interaction, since the distance range is flexible after staining with primary antibody more secondary, but supposes firm evidence that such interaction occurs in vivo. Finally, crosslinking of CD81 with monoclonal antibodies against CD81 or CD4 induces the accumulation of SAMHD1 near the plasma membrane in a CD81 dependent manner. SAMHD1 is a cellular inhibitor of HIV-1 RT in resting myeloid cells and resting CD4 + T cells. Although widely studied in recent years, the mechanisms that control this process are not fully known (Ahn, 2016, Functional organization of human SAMHD1 and mechanisms of HIV-1 restriction, Biol Chem. 397: 373-379; Ballana and Este , 2015, SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction, Trends Microbiol. 23: 680-692). Phosphorylation of SAMHD1 in T592 appears to be important for the control of RNase activity (Choi et al., 2015, SAMHD1 specifically restrictedts retroviruses through its RNase activity, Retrovirology, 12:46; Cribier et al., 2013, Phosphorylation of SAMHD1 by cyclin A2 / CDK1 regulates its restriction activity towards HIV-1, Cell Rep. 3: 1036-1043; Ryoo et al., 2014, The ribonuclease activity of SAMHD1 is required for HIV-1 restriction, Nat Med. 20: 936-941 ; Welbourn et al., 2013, Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1, J Virol. 87: 11516-11524; White et al., 2013, The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation, Cell Host Microbe, 13: 441-451) and dNTPase (Pauls et al., 2014, Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells, J Immunol. 193: 1988-1997; Ruiz et al., 2015, Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages, Cell Cycle. 14: 1657-1665; Tang et al., 2015, Impaired dNTPase activity of SAMHD1 by phosphomimetic mutation of Thr-592, J Biol Chem. 290: 26352-26359; Yan et al., 2015, CyclinA2-Cyclin-dependent Kinase Regulates SAMHD1 Protein Phosphohydrolase Domain, J Biol Chem. 290: 13279-13292) of SAMHD1. However, it has recently been suggested that such phosphorylation cannot fully explain the restrictive effect of SAMHD1 (Antonucci et al., 2016, SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity, Nature medicine, 22: 1072 -1074; Bhattacharya et al., 2016, Effects of T592 phosphomimetic mutations on tetramer stability and dNTPase activity of SAMHD1 cannot explain the retroviral restriction defect, Scientific reports, 6: 31353). The exonuclease activity of SAMHD1 is also controversial, and some recent studies indicate that it is not related to its function in viral restriction (Antonucci et al., 2016, SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity, Nature medicine, 22: 1072-1074; Welbourn and Strebel, 2016, Low dNTP levels are necessary but may not be sufficient for lentiviral restriction by SAMHD1, Virology, 488: 271-277). Such exonuclease activity could be due even to contaminants in the sample (Seamon et al., 2015, SAMHD1 is a singlestranded nucleic acid binding protein with no active site-associated nuclease activity, Nucleic Acids Res. 43: 6486-6499). In the absence of CD81 we observe that the expression of SAMHD1 is induced and its dNTPase activity is increased, without noticeable effects on the phosphorylation levels of SAMHD1. These results clearly indicate that CD81 is an important regulator in restricting the replication of HIV-1 by SAMHD1. When the expression of CD81 is depleted the expression of SAMHD1, and therefore its SAMHD1 dNTPase activity increases, reducing intracellular levels of dNTPs, and preventing HIV-1 RT. On the contrary, when CD81 is overexpressed, the expression, and therefore the activity of SAMHD1 is reduced, the cellular content of dNTs is greater, allowing a huge increase in the HIV-1 RT. In addition, the C-terminal domain of CD81 is essential in this process, as demonstrated by the use of a C-terminal deletion mutant or blocking peptides with the sequence of the C-terminal region of CD81. In summary, CD81 regulates the early replication of HIV-1 through its direct association with SAMHD1 and the regulation of its dNTPase activity, through the modulation of its expression and the control of its subcellular location. Evidence that SAMHD1 is included in TEMs highlights the importance of these membrane microdomains during HIV-1 replication, not only in the entry and assembly phases, but also in the RT phase of the viral cycle.
权利要求:
Claims (10) [1] 1. Use of agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in the preparation of a medicament for the treatment and / or prevention of 5 diseases in which the volume of dNTPs is relevant, where agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of (i) Small interfering RNA (siRNA) complementary to the protein mRNA CD81; 10 (ii) peptides comprising the sequence CCGIRNSSVY (SEQ ID NO .: 10); (iii) antibodies that specifically recognize the C-terminal domain of the CD81 protein, where the C-terminal domain of the CD81 protein is the CCGIRNSSVY sequence (SEQ ID NO .: 10); Y (iv) vectors for gene therapy and for the functional elimination of the gene that codes for 15 the CD81 protein comprising the CRISPR / Cas9 system; where the diseases in which the volume of dNTPs is relevant is selected from the group consisting of infections caused by retroviruses, infections caused by DNA viruses and infections caused by DNA viruses that have retrotranscription steps in their viral cycle. [2] 2. The use according to claim 1, characterized in that the infections caused by retroviruses are selected from the group consisting of infections caused by HIV and HTLV. The use according to claim 1, characterized in that the infections caused by DNA viruses are selected from the group consisting of infections caused by herpes simplex virus type I (HSV-1), herpes simplex virus type II ( HSV-2), human herpes virus 3, human herpes virus 4, human herpes virus 5, human herpes virus 6, human herpes virus 7 and human herpes virus 8. [4] 4. The use according to claim 1, characterized in that the infections caused by DNA viruses that have in their viral cycle retrotranscription steps are selected from the group consisting of infections caused by the Hepatitis B virus. [5] 5. The use according to any of the preceding claims, characterized in that the small interfering RNA is selected from the group consisting of sequences that comprise or, alternatively, consist of CAATTTGTGT CCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9). [6] 6. The use according to claims 1-4, characterized in that the vector for gene therapy comprising the CRISPR / Cas9 system comprises as a target sequence a sequence comprising or, alternatively, consisting of CACCGGCTGGCTGGAGGCGTGATCCGT (SEQ ID NO .: 11) or 10 CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: 12). [7] 7. Screening method to identify agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 comprising the steps of: a) Selecting candidate agents, preferably from a library of 15 compounds; b) Determine if any of these agents is capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 in cells expressing both proteins; c) Select those agents that promote the reduction / inhibition described in the step b); and, 20 d) Optionally, produce those agents selected in step c). [8] 8. The method according to claim 7, characterized in that the candidate agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of small interfering RNA (siRNA) that interferes with The expression of the gene encoding the CD81 protein, micro RNA (miRNA), shRNA, peptides, small molecules, antibodies and vectors for gene therapy and for the functional elimination of the gene encoding the CD81 protein comprising the CRISPR / system Cas9. [9] 9. Combination of medicines for the treatment of HIV infection 30 comprising at least three drugs selected from at least two different classes of drugs to treat HIV infection, characterized in that the combination comprises at least one drug belonging to the class of nucleoside analogue reverse transcriptase inhibitor drugs , in which said The drug is an agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1, where the agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of 5 (i) small interfering RNA (siRNA) complementary to the CD81 protein mRNA; (ii) peptides comprising the sequence CCGIRNSSVY (SEQ ID NO .: 10); (iii) antibodies that specifically recognize the C-terminal domain of the protein CD81, where the C-terminal domain of the CD81 protein is sequence 10 CCGIRNSSVY (SEQ ID NO .: 10); Y (iv) vectors for gene therapy and for the functional elimination of the gene encoding the CD81 protein comprising the CRISPR / Cas9 system. [10] 10. The combination according to claim 9, characterized in that the RNA Small interference is selected from the group consisting of sequences that comprise or, alternatively, consist of CAATTTGTGT CCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9) . [11] 11. The combination according to claim 9, characterized in that the vector for The gene therapy comprising the CRISPR / Cas9 system comprises as a target sequence a sequence that comprises or, alternatively, consists of, CACCGGCTGGCTGGAGGCGTGATCCGT (SEQ ID NO .: 11) or CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: 12). 12. The use of agents capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 according to claim 1, characterized in that the disease in which the volume of dNTPs is relevant is HIV infection and why The agent capable of reducing / inhibiting the association of tetraspanin CD81 with the enzyme SAMHD1 is selected from the group consisting of small interfering RNA selected from the group consisting of 30 sequences that comprise or, alternatively, consist of CAATTTGTGT CCCTCGGGC (SEQ ID NO .: 3), CACCTTCTATGTAGGCATC (SEQ ID NO .: 8) and CACGTCGCCTTCAACTGTA (SEQ ID NO .: 9), a peptide comprising or, alternatively, consists in the sequence CCGIRNSSVY (SEQ ID NO .: 10) and a vector for gene therapy comprising the system CRISPR / Cas9 comprises as a target sequence a sequence that comprises or alternatively consists of CACCGGCTGGCTGGAGGCGTGATCCGT (SEQ ID NO .: 11) or CACCGGCGCCCAACACCTTCTATGTGT (SEQ ID NO .: 12). Figure 1 Figure 2 Figure 2 (continued) Figure 2 (continued) Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 7 (continued) Figure 8 Figure 8 (continued) Figure 9 2017-03-14 Sequence listing 901 949 SEQUENCE LISTING <110> UNIVERSITY AUTONOMA DE MADRID Princess Hospital Foundation <120> Use of CD81 as a therapeutic target to regulate intracellular levelsof dNTPs <130> 901 949 <160> 13 <170> BiSSAP 1.3.6 <210> 1 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> CD81pept <400> 1Arg Arg Arg Arg Arg Arg Arg Cys Cys Gly Ile Arg Asn Ser Ser Val1 5 10 15Tyr <210> 2 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Scrambled <400> 2Arg Arg Arg Arg Arg Arg Arg Tyr Ser Val Asn Ile Cys Arg Gly Cys1 5 10 15To be <210> 3 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> siCD81 <400> 3caatttgtgt ccctcgggc 19 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> First <400> 4caggattctt gcctggagct g 21 2017-03-14 Sequence listing 901 949 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> First <400> 5 ggagcagcag gaagcactat g twenty-one <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> First <400> 6 tgtgtgcccg tctgttgtgt twenty <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> First <400> 7 cgagtcctgc gtcgagagat twenty <210> 8 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ARNip <400> 8 caccttctat gtaggcatc 19 <210> 9 <211> 19 <212> RNA <213> Artificial Sequence <220> <223> ARNip <400> 9 cacgtcgcct tcaactgta 19 <210> 10 <211> 10 <212> PRT 2 2017-03-14 Sequence listing 901 949 <213> Artificial Sequence <220> <223> CD81 Peptide <400> 10Cys Cys Gly Ile Arg Asn Ser Ser Val Tyr1 5 10 <210> 11 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> CRISP / Cas9 target sequence <400> 11caccggctgg ctggaggcgt gatccgt 27 <210> 12 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> CRISP / Cas9 target sequence <400> 12caccggcgcc caacaccttc tatgtgt 27 <210> 13 <211> 22 <212> RNA <213> Artificial Sequence <220> <223> SiControl <400> 13aauucucccg aacgugucac gu 22
类似技术:
公开号 | 公开日 | 专利标题 JP2020188757A|2020-11-26|Methods and compositions for rna-guided treatment of hiv infection Usami et al.2015|SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef Baldauf et al.2012|SAMHD1 restricts HIV-1 infection in resting CD4+ T cells Séror et al.2011|Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection Miyakawa et al.2009|BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction US20190175727A1|2019-06-13|Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides JP2019506156A|2019-03-07|Methods and compositions for RNA-induced treatment of HIV infection Valera et al.2015|The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation Ebina et al.2004|Role of Nup98 in nuclear entry of human immunodeficiency virus type 1 cDNA Dicks et al.2018|Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction Alais et al.2012|Functional mechanisms of the cellular prion protein | associated anti-HIV-1 properties Weiss et al.2012|Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth Fujinaga et al.1995|Extracellular Nef protein regulates productive HIV-1 infection from latency. Ko et al.2013|PA28γ is a novel corepressor of HTLV-1 replication and controls viral latency Drayman et al.2016|p53 elevation in human cells halt SV40 infection by inhibiting T-ag expression Wang et al.2015|Viral restriction activity of feline BST2 is independent of its N-glycosylation and induction of NF-κb activation ES2688161B1|2019-09-05|Use of CD81 as a therapeutic target to regulate intracellular DNTPS levels Alvarez et al.2011|WFDC1 expression identifies memory CD4 T-lymphocytes rendered vulnerable to cell-cell HIV-1 transfer by promoting intercellular adhesive junctions Marrero-Hernández et al.2019|HIV-1 Nef targets HDAC6 to assure viral production and virus infection Lv et al.2013|Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin Dürr et al.2014|Targeting cellular cofactors in HIV therapy Ulferts et al.2021|Subtractive CRISPR screen identifies the ATG16L1/vacuolar ATPase axis as required for non-canonical LC3 lipidation US20140010839A1|2014-01-09|Method of screening antiretroviral compounds and vaccine CA3069179A1|2019-01-17|Targeting the hdac2-sp3 complex to enhance synaptic function Wang et al.2015|GB virus type C E2 protein inhibits human immunodeficiency virus type 1 gag assembly by downregulating human ADP-ribosylation factor 1
同族专利:
公开号 | 公开日 ES2688161B1|2019-09-05| ES2688161R2|2018-11-28| WO2018178499A3|2018-11-15| WO2018178499A2|2018-10-04|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题
法律状态:
2018-10-31| BA2A| Patent application published|Ref document number: 2688161 Country of ref document: ES Kind code of ref document: A2 Effective date: 20181031 | 2018-11-28| EC2A| Search report published|Ref document number: 2688161 Country of ref document: ES Kind code of ref document: R2 Effective date: 20181121 | 2019-09-05| FG2A| Definitive protection|Ref document number: 2688161 Country of ref document: ES Kind code of ref document: B1 Effective date: 20190905 |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 ES201700345A|ES2688161B1|2017-03-30|2017-03-30|Use of CD81 as a therapeutic target to regulate intracellular DNTPS levels|ES201700345A| ES2688161B1|2017-03-30|2017-03-30|Use of CD81 as a therapeutic target to regulate intracellular DNTPS levels| PCT/ES2018/070291| WO2018178499A2|2017-03-30|2018-04-02|Use of cd81 as therapeutic target for regulating intracellular levels of dntps| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|